Legato Capital Management LLC Acquires 5,277 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Legato Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 117.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 9,784 shares of the biopharmaceutical company's stock after acquiring an additional 5,277 shares during the period. Regeneron Pharmaceuticals makes up approximately 0.8% of Legato Capital Management LLC's investment portfolio, making the stock its 9th largest holding. Legato Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $6,205,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Venturi Wealth Management LLC boosted its position in Regeneron Pharmaceuticals by 77.4% in the first quarter. Venturi Wealth Management LLC now owns 612 shares of the biopharmaceutical company's stock valued at $388,000 after buying an additional 267 shares during the last quarter. Beacon Investment Advisory Services Inc. boosted its position in Regeneron Pharmaceuticals by 7.1% in the first quarter. Beacon Investment Advisory Services Inc. now owns 26,259 shares of the biopharmaceutical company's stock valued at $16,654,000 after buying an additional 1,751 shares during the last quarter. M. Kulyk & Associates LLC boosted its position in Regeneron Pharmaceuticals by 24.5% in the first quarter. M. Kulyk & Associates LLC now owns 2,687 shares of the biopharmaceutical company's stock valued at $1,704,000 after buying an additional 528 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after purchasing an additional 19 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its position in Regeneron Pharmaceuticals by 0.6% in the 1st quarter. KLP Kapitalforvaltning AS now owns 48,688 shares of the biopharmaceutical company's stock worth $30,879,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of NASDAQ REGN traded down $1.54 during mid-day trading on Friday, reaching $563.10. 752,630 shares of the company's stock were exchanged, compared to its average volume of 1,121,459. The firm has a market capitalization of $60.79 billion, a price-to-earnings ratio of 14.34, a PEG ratio of 2.14 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company's 50-day moving average is $543.18 and its 200-day moving average is $610.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the company earned $9.55 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Citigroup lowered their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. Finally, UBS Group upped their target price on Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a "neutral" rating in a research note on Friday, July 11th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $837.61.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.